The Role of Bisphosphonates in Breast Cancer Treatment
Description: Much-anticipated and highly-disappointing results were presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium. In an international trial of 3,360 women, the bone-building drug Zometa, failed to prevent breast cancer recurrence and found no disease-free survival benefit among the majority of women with Stage II/III disease.
Bisphosphonates role in the treatment of breast cancer has been an active area of research focus, as previous clinical trials had shown that the class of drugs may have anti-cancer activity.
Sharon Giordano, M.D., associate professor in MD Anderson's Department of Breast Medical Oncology, was a commentator on the press program shares her perspective
Shared By : mdanderson
Posted on : 12/28/10
Added : 7 years ago